JP2020507332A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507332A5
JP2020507332A5 JP2019544614A JP2019544614A JP2020507332A5 JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5
Authority
JP
Japan
Prior art keywords
cancer
protein
pharmaceutical composition
composition according
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019544614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507332A (ja
JP7712060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/053918 external-priority patent/WO2018149982A1/en
Publication of JP2020507332A publication Critical patent/JP2020507332A/ja
Publication of JP2020507332A5 publication Critical patent/JP2020507332A5/ja
Priority to JP2023133276A priority Critical patent/JP2023160838A/ja
Application granted granted Critical
Publication of JP7712060B2 publication Critical patent/JP7712060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019544614A 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ Active JP7712060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133276A JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156718 2017-02-17
EP17156718.3 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133276A Division JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Publications (3)

Publication Number Publication Date
JP2020507332A JP2020507332A (ja) 2020-03-12
JP2020507332A5 true JP2020507332A5 (enExample) 2021-03-25
JP7712060B2 JP7712060B2 (ja) 2025-07-23

Family

ID=58094260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544614A Active JP7712060B2 (ja) 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20240170928A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250024816A (ko) * 2015-06-18 2025-02-19 백심 아게 병용 요법을 위한 vegfr-2 표적화 dna 백신
KR20210058825A (ko) * 2018-09-05 2021-05-24 백심 아게 병용 요법용 신생항원 표적화 dna 백신
EP4090321A1 (en) * 2020-01-13 2022-11-23 Vaximm AG Salmonella-based dna vaccines in combination with an antibiotic
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
LT2794849T (lt) 2011-12-22 2017-12-11 Vaximm Ag Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas
DK2869836T3 (da) * 2012-07-05 2019-11-25 Vaximm Ag Dna-vaccine til anvendelse hos patienter med pankreascancer
EP2988762B1 (en) * 2013-04-25 2018-06-06 Vaximm AG Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
DK3082850T3 (da) * 2013-12-18 2019-10-07 Vaximm Gmbh Msln-targeteret dna-vaccine til cancerimmunterapi
WO2015142875A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
KR20250024816A (ko) * 2015-06-18 2025-02-19 백심 아게 병용 요법을 위한 vegfr-2 표적화 dna 백신
KR20190027834A (ko) 2016-07-13 2019-03-15 백심 아게 암 면역요법용 dna 백신을 제조하기 위한 방법

Similar Documents

Publication Publication Date Title
JP2020511139A5 (enExample)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Piper et al. Glioma stem cells as immunotherapeutic targets: advancements and challenges
JP2020507332A5 (enExample)
JP6945301B2 (ja) Hpvおよび関連する疾病のための免疫増強治療ワクチン
RU2016129044A (ru) Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
Fan et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
US10987432B2 (en) Therapeutic delivery and expression system, methods and uses thereof
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
Mei et al. Combining DNA vaccine and AIDA-1 in attenuated Salmonella activates tumor-specific CD4+ and CD8+ T-cell responses
JP2018517419A5 (enExample)
Zhao et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
Weintraub et al. Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
BR112021001117A2 (pt) células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
CN110408634B (zh) 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
Riederer et al. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
Jia et al. The future of cancer vaccines against colorectal cancer
EP2826856A1 (en) Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2019112977A (ru) Днк-вакцина, нацеленная на wt1, для комбинированной терапии
Sampath et al. Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses
Bella et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis